What Is MLR Review? A Complete Guide for Pharma and Medical Writers

Every promotional claim a pharmaceutical company makes in an email, sales aid, banner, or slide has to survive MLR review before it ever reaches a physician. It is the single biggest bottleneck between a good idea and an approved asset, and for most teams it is the part of the job nobody enjoys.

This guide explains what MLR review actually is, how the process works, who is involved, why it takes so long, and what is finally starting to change.

What is MLR review?

MLR review is the process by which a pharmaceutical company's Medical, Legal, and Regulatory teams review and approve promotional and scientific content before it is published. Its purpose is to confirm that every claim is accurate, fairly balanced, and fully substantiated by an approved source, so the company stays compliant with regulations like the FDA's rules on prescription drug promotion and the equivalent codes in other markets.

In practice, MLR review is a sign-off gate. A piece of content, usually called a "job" or an "asset," is submitted for review, each reviewer adds comments, the creator revises, and the cycle repeats until every reviewer signs off. Only then can the asset go live.

It sounds simple. It almost never is.

What does MLR stand for?

MLR stands for Medical, Legal, and Regulatory, the three functions that have to approve promotional material:

• Medical confirms that every claim is scientifically accurate and properly supported by the evidence.
• Legal checks for liability, intellectual property, and contractual risk.
• Regulatory confirms the piece complies with the relevant promotional rules and the product's approved label (the prescribing information).

You will also hear the process itself called promotional review or copy review. The cross-functional team that carries it out is usually called the Promotional Review Committee (PRC), so PRC names the committee, not the process, even though the two get used interchangeably in everyday conversation.

One important note for global teams: MLR and PRC are essentially US terms. As experienced reviewers like to point out, the UK and European codes don't talk about "review" at all; they refer to medical approval, with a single named signatory who is personally accountable for the final piece. The underlying work is similar everywhere, but the vocabulary, and the accountability model behind it, are not. If you operate across regions, don't assume the US workflow maps cleanly onto the ABPI or EFPIA world.

Who is responsible for MLR review?

Responsibility is split across the three functions, and there is no single model the whole industry follows. The clearest data we have describes the medical side specifically. In a 2024 promotional-review benchmark from Canopy, when teams were asked who in Medical Affairs owns promotional review, 44% pointed to the medical director, followed by medical information (23%) and a dedicated promotional-review function (just 15%). In other words, in the case of medical, for nearly half of companies the work lands on the desk of a senior physician who already has plenty of other responsibilities.

Accountability is a different question from who does the work, and here practitioners are clearer. In a 2024 audience poll run by Impatient Health, MLR professionals were asked who should hold primary accountability for compliance across the process: 52% chose a cross-functional team with shared accountability, well ahead of a dedicated compliance officer (19%) or senior medical leadership alone (11%). MLR is a team sport, and the most experienced reviewers tend to insist on keeping medical and regulatory as distinct voices rather than blending them into one role, because each function watches for a different kind of risk.

A practical pattern many teams use: route routine medical review to a brand's medical-information lead so the medical director isn't pulled into every single job, and reserve senior sign-off for the pieces that genuinely need it.

How the MLR review process works, step by step

Although every company's workflow differs in the details, almost all of them follow the same five stages:

1. Create and submit. Marketing, or an external agency, drafts the asset, gathers the supporting references, links each claim to its source, and in most cases uploads the package to a Life Sciences DAM (Digital Asset Management) platform such as Veeva Vault PromoMats, Aprimo, or Vodori (with Salesforce's Life Sciences Cloud DAM module on the roadmap for the second half of 2026), then submits it for review.
2. Review. Each reviewer (medical, legal, regulatory) reads the piece, checks every claim against its cited source, and leaves comments.
3. Revise and resubmit. The creator addresses the comments and sends it back. This stage is where the cycle lives, and where it can repeat many times.
4. Approve and date. Once all reviewers sign off, the asset is approved, given an expiry date, and locked.
5. Distribute. The approved asset is released to the field or the channel.

Stage 2 is where the flags go up. Medical reviewers catch references that are missing, incomplete, or too weak to support a claim; regulatory reviewers catch inconsistencies with the prescribing information; legal reviewers catch contractual or liability risk. Most individual issues are quick to spot. What actually consumes the calendar is stage 3, and specifically how many times a piece has to loop back through it before every function is satisfied.

Why MLR review takes so long

Industry benchmarks put the average content approval cycle at around 21 days, and that is just the average. Reviewers routinely describe promotional pieces that come back ten or more times, carrying thousands of accumulated comments, before they finally clear. We unpack the economics of that in the $30 billion content-waste problem.

The time burden on reviewers is real and measurable. In the Canopy data, roughly two out of three reviewers spend at least 15% of their working week on promotional review, and about one in three spend 25% or more, which can mean ten to fifteen or more hours a week, frequently spilling into evenings and weekends. Medical directors carry their own share: in a separate Impatient Health poll, 38% estimated they spend between 10% and 20% of their total time on MLR, and another 27% put it between 21% and 30%.

So where does all that time go? Mostly to problems that have nothing to do with medical complexity:

• Submissions arrive that aren't linked and anchored. When a draft lands without each claim tied to a specific, highlighted line in its source PDF, the reviewer has to do the forensic work of hunting for the evidence. Many simply refuse: the piece does not get reviewed until it is properly linked and anchored.
• Reference errors and claim drift. Citing an abstract instead of the primary data, reusing a claim from an old deck in a new context it no longer supports, or the quiet addition of a marketing superlative such as "best," "unique," or "first-line" that turns a previously approved claim into a noncompliant one. We cover this failure mode in detail in why your MLR process is broken before it starts.
• The marketing versus medical tug-of-war. The loudest friction is between the marketing team that writes the ambitious claim and the medical and regulatory reviewers who have to substantiate it. The back-and-forth that happens before a piece is even formally submitted is, for many teams, the single biggest time sink in the whole process.
• No capacity buffer. When demand spikes (at launch, for instance), most teams have no plan B. In another Impatient Health poll, 53% said they simply absorb the extra workload with existing staff, and only 5% had invested in technology to handle the surge.

Add it up and a pattern emerges: MLR is slow not because review is hard, but because what arrives for review usually isn't ready to be reviewed.

MLR review and AI: where it helps, and where it hurts

It is tempting to throw a general-purpose AI assistant at the problem. Don't, at least not a generic one.

Tools like ChatGPT or Microsoft Copilot are not regulatory-ready. They treat facts as suggestions, they are not anchored to your approved label or your reference library, and they will confidently invent a citation that does not exist. In an MLR context, a single hallucinated or misattributed reference slipping into a submission is exactly the kind of error the whole process exists to catch.

Practitioners see this clearly. In the Impatient Health polls, asked where AI offers the most genuine near-term value in MLR, the top answers were speeding up initial data gathering and fact-checking (27%) and identifying inconsistencies or missing information in materials (27%), both of them narrow, assistive tasks. Tellingly, asked in a related poll which AI claim is most overstated, the top answer (again 27%) was "speeding up compliance and regulatory processes." The people doing the work are optimistic about AI as an assistant and skeptical of it as a replacement.

That instinct is right, and it shows up in how they think about accountability. Asked who is responsible if an AI-assisted piece causes a compliance breach, 39% of those polled pointed to the human who performed the final review, more than blamed the team, the department head, or the AI vendor. The lesson is consistent: keep a human in the driver's seat, even in an increasingly automated car. AI should make the reviewer faster and the submission cleaner; it should never make the decision.

How to speed up MLR review

The fix is not to hire more agencies to produce more drafts. It is to make sure that what reaches review is already in good shape. The principle is to shift compliance left, into the drafting phase, instead of discovering every problem at the review meeting.

A few moves consistently help:

• Build, and actually maintain, a core-claims library. A curated set of pre-approved claims, each one locked to its approved reference, lets marketing assemble new content from blocks that have already passed review. Everyone agrees this is best practice; the hard part, as veterans wryly note, is funding and maintaining it once the launch excitement fades.
• Link and anchor during drafting, not after. Every claim should arrive at review already tied to the exact page, ideally the exact highlighted sentence, of its source. When that is true, the reviewer verifies instead of hunting, and the 21-day cycle starts to collapse.
• Format references cleanly and consistently. Sloppy or inconsistent citations generate their own review comments. If you need to turn a PubMed record into a clean reference fast, our free AMA citation generator does it in one paste.

This is exactly the gap PharmaText.ai was built to close. Our Precision Traceability engine anchors every claim to specific coordinates in your uploaded PDFs as the content is drafted, so the package that reaches MLR is already linked, already anchored, and ready to be verified rather than fixed. The goal is simple: turn first-round approval from a lucky outcome into the normal one. You can read about why this work belongs upstream of Veeva.

MLR review FAQ

What does MLR stand for? Medical, Legal, and Regulatory, the three functions that review and approve pharmaceutical promotional content before publication.

What is MLR in pharma? In pharma, MLR is the mandatory internal review that confirms a promotional or scientific asset is accurate, balanced, compliant with the product's approved label, and substantiated by approved references before it can be used.

What is the difference between MLR and PRC? They are not quite the same thing. MLR, also called promotional or copy review, is the review process itself. The PRC, or Promotional Review Committee, is the cross-functional team that performs it. Both terms are US-centric; UK and European codes instead refer to medical approval by a named signatory.

How long does MLR review take? Industry benchmarks put the average approval cycle at roughly 21 days, but poorly prepared pieces can cycle back many times and take far longer. The biggest driver of speed is how review-ready the submission is on day one.

Who signs off on MLR review? Medical, legal, and regulatory reviewers each sign off. In many companies the medical director is the primary medical reviewer, though accountability is increasingly held by a cross-functional team.

Related: see why your MLR process is broken before review even starts, the $30 billion content-waste problem and the 21-day approval cycle, or format a clean primary-source citation with our free AMA citation generator.

Sources: data presented at 2024 industry webinars by Canopy and Impatient Health; the underlying reports are not publicly available.